Ikena Oncology Inc reports results for the quarter ended in March - Earnings Summary

ImageneBio

13/05/2024 23:34

* Ikena Oncology Inc  IKNA.OQ  reported a quarterly adjusted
loss
of 33 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -39 cents.  The mean expectation of four analysts for the
quarter was for a loss of 41 cents per share. Wall Street
expected results to range from -44 cents to -39 cents per share.
    * Reported revenue was zero​; analysts expected $1.75
million. 
    * Ikena Oncology Inc's reported EPS for the quarter was a
loss
of 33 cents​.
    * The company reported a quarterly loss of $16.15 million.
    * Ikena Oncology Inc shares had fallen by 9.2% this
quarter and
lost 34.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Ikena Oncology
Inc is $8.00 
This summary was machine generated from LSEG data May 13 at
10:34 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.41          -0.33          Beat
 Dec. 31 2023      -0.43          -0.47          Missed
 Sep. 30 2023      -0.43          -0.40          Beat
 Jun. 30 2023      -0.47          -0.44          Beat